Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
- 1 February 1992
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 23 (1) , 57-62
- https://doi.org/10.1007/bf01831476
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancerJournal of Steroid Biochemistry, 1990
- Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedioneCancer Chemotherapy and Pharmacology, 1990
- Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibitionJournal of Steroid Biochemistry, 1989
- Importance of estrogen sulfates in breast cancerJournal of Steroid Biochemistry, 1989
- Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast CancerDrugs, 1988
- Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancerCancer Chemotherapy and Pharmacology, 1987
- Aromatase inhibitors and the treatment of breast cancerJournal of Steroid Biochemistry, 1986
- Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1985
- Additive effects of aminoglutethimide testololactone, and 4-hydroxyandrostenedione as inhibitors of aromataseThe Journal of Steroid Biochemistry and Molecular Biology, 1984
- EFFECTS OF AMINOGLUTETHIMIDE ON ADRENAL STEROID SECRETIONClinical Endocrinology, 1983